This activity is expired and is no longer available for CME credit.


Rapid Response from Vienna 2018: Seeking the Right Dose of Anti-VEGF Therapy for Age-related Macular Degeneration and Diabetic Retinopathy

Author(s)/Faculty: Darius M. Moshfeghi, MD; Peter K. Kaiser, MD; Sebastian Wolf, MD, PhD
Release Date: 9/28/2018Expiration Date: 9/27/2019
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
The integration of anti-vascular endothelial growth factor (VEGF) intravitreal therapies into treatment protocols for patients with neovascular retinal diseases has revolutionized visual and anatomical outcomes. Even with the observed robust responses to anti-VEGF therapy, many questions remain pertaining to dosing schedules of therapy and identification of patients who may benefit with longer intervals between treatment doses. Adding to these questions are concerns that patients on individualized dosing schedules may be receiving under- or overtreatment. In this activity, Rapid Response from Vienna 2018, experts in the field provide overview, analysis, and discussion regarding the most pertinent scientific data presented during the Congress proceedings pertaining to current and emerging evidence of optimal dosing strategies with anti-VEGF therapy for the treatment of patients with wet age-related macular degeneration, as well as the effectiveness of various dosage strategies utilized in the management of patients with diabetic retinopathy.